Navigation Links
Signalife Sees Accretive Purchase and Financial Commitments
Date:3/17/2008

/www.Signalife.com" target="_new">http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Signalife Wins Second Frost & Sullivan Technology Award
2. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
3. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
4. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
5. U.S. Patent 7,299,083 Awarded to Signalife
6. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
7. Signalife Continues to Procure Purchase Orders, Revenues
8. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
9. Signalife Receives Another $3.3 Million Sales Orders
10. Signalife Achieves $1.98 Million Sales Orders Thus Far
11. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... /CNW/ - Softchoice, a leading North American IT solutions and managed ... of two Cisco® Partner Summit Country awards. ... Security Partner of the Year for Canada ... in Montreal . "We ... awards at this year,s conference," said David MacDonald , ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... -- Oxford Finance LLC ("Oxford"), a specialty finance firm ... services companies, today announced the closing of a $10 ... a diagnostic testing company focused on improving the accuracy ... improved outcomes.  Proceeds of the loan will be used ... its products in the U.S. and China ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Oxford Finance Provides $10 Million Debt Financing to Celula 2
... at American Society of Clinical Oncology , , ... presented data demonstrating the use of ChemoFX(R), a chemosensitivity ... the colorectal cancer cells of individual patients. Results ... colorectal cultures tested, eight percent were responsive to cetuximab, ...
... KVISTGAARD, Denmark, June 1 Detailed ... Saturday at the,ASCO Annual Meeting in Orlando. The presentation was ... School , and the Dana-Farber Cancer,Institute who is also the ... The more detailed analysis supports the headline data that were ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Clinical Oncology (ASCO) annual meeting. The meeting is being held ... , The presentation, entitled "A Phase II Study of Intravenous ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 2PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 3
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... today in Science , researchers from Cambridge, Glasgow ... in how transcription factors, the proteins that bind to ... function over large evolutionary distances. The text books ... they regulate by binding to short, sequence-specific lengths of ...
... reef ecosystems are highly valued for their diverse ... reef fishing and tourism industries, but they are ... over-exploitation. The National Institute for Mathematical ... for its Investigative Workshop, Modeling Reef Ecosystems, to ...
... info@engconfintl.org ) and the Cell Culture Engineering ... proud to announce Prof. Michael J. Betenbaugh, ... Culture Engineering Award.,Mike Betenbaugh ( http://www.jhu.edu/chembe/faculty-template/MichaelBetenbaugh.html ) ... at Johns Hopkins University, Baltimore, MD, USA. ...
Cached Biology News:Rewiring of gene regulation across 300 million years of evolution 2Michael Betenbaugh wins 2010 Cell Culture Engineering award 2
Cytofix Buffer 100 mls...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
Biology Products: